|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US7063967B2
(en)
|
1997-05-08 |
2006-06-20 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
|
AU773921B2
(en)
*
|
1997-05-08 |
2004-06-10 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
|
US7541020B2
(en)
*
|
1997-05-08 |
2009-06-02 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
|
US6303347B1
(en)
*
|
1997-05-08 |
2001-10-16 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
|
US6764840B2
(en)
|
1997-05-08 |
2004-07-20 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
|
ID30407A
(id)
|
1999-05-13 |
2001-11-29 |
American Cyanamid Co |
Formulasi-formulasi kombinasi bahan penambah
|
|
EP1229931A4
(en)
*
|
1999-10-07 |
2003-05-28 |
Corixa Corp |
FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
|
|
SI1650221T1
(sl)
|
2000-02-23 |
2012-09-28 |
Glaxosmithkline Biolog Sa |
Nove spojine
|
|
WO2001062893A2
(en)
|
2000-02-25 |
2001-08-30 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US6699846B2
(en)
*
|
2000-03-17 |
2004-03-02 |
Corixa Corporation |
Mono- and disaccharides for the treatment of nitric oxide related disorders
|
|
WO2001078777A2
(en)
*
|
2000-04-13 |
2001-10-25 |
Mossman, Sally |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
|
|
PT1284740E
(pt)
*
|
2000-05-19 |
2008-07-09 |
Corixa Corp |
Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos
|
|
US20030139356A1
(en)
*
|
2001-05-18 |
2003-07-24 |
Persing David H. |
Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
|
|
US20030105032A1
(en)
*
|
2000-05-19 |
2003-06-05 |
Persing David H. |
Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds
|
|
PT2133100E
(pt)
|
2000-06-20 |
2012-01-11 |
Corixa Corp |
Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
|
|
CA2417806C
(en)
|
2000-08-04 |
2011-05-10 |
Corixa Corporation |
New immunoeffector compounds
|
|
WO2002038177A2
(en)
*
|
2000-11-10 |
2002-05-16 |
Wyeth Holdings Corporation |
Adjuvant combination formulations
|
|
US20060142202A1
(en)
*
|
2000-12-08 |
2006-06-29 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
|
BR0116756A
(pt)
|
2000-12-28 |
2005-01-04 |
Wyeth Corp |
Proteìna protetora recombinante de streptococcus pneumoniae e uso da mesma
|
|
US20070128229A1
(en)
*
|
2002-04-12 |
2007-06-07 |
Wyeth |
Surface proteins of Streptococcus pyogenes
|
|
CN101124237A
(zh)
*
|
2001-04-13 |
2008-02-13 |
惠氏 |
酿脓链球菌的表面蛋白
|
|
KR100886095B1
(ko)
|
2001-04-16 |
2009-02-27 |
와이어쓰 홀딩스 코포레이션 |
폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스 뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
|
|
CA2446788A1
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
|
US7030094B2
(en)
*
|
2002-02-04 |
2006-04-18 |
Corixa Corporation |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
|
|
US6911434B2
(en)
*
|
2002-02-04 |
2005-06-28 |
Corixa Corporation |
Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
|
|
RU2289585C2
(ru)
*
|
2002-02-04 |
2006-12-20 |
Корикса Корпорейшн |
Новые аминоалкилглюкозаминидфосфатные соединения, иммуностимулирующая фармацевтическая композиция, их содержащая, и способ индуцирования иммунного ответа
|
|
US20030190333A1
(en)
*
|
2002-02-04 |
2003-10-09 |
Corixa Corporation |
Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
|
|
RU2288723C2
(ru)
*
|
2002-02-04 |
2006-12-10 |
Корикса Корпорейшн |
Профилактическое и терапевтическое лечение инфекционных и других заболеваний с помощью иммуноэффективных соединений
|
|
IL163305A
(en)
|
2002-02-04 |
2010-10-31 |
Corixa Corp |
Azacycloalkyl glucosaminide phosphate as immunoeffector compounds and pharmaceutical compositions for propylactic and therapeutic treatment of infectious and therapeutic treatment of infectious and other diseases comprising the same
|
|
WO2003065806A1
(en)
*
|
2002-02-04 |
2003-08-14 |
Corixa Corporation |
New immunoeffector compounds
|
|
AU2003213118A1
(en)
*
|
2002-02-15 |
2003-09-09 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
|
US7351413B2
(en)
*
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
|
US7030129B2
(en)
*
|
2002-02-22 |
2006-04-18 |
3M Innovative Properties Company |
Method of reducing and treating UVB-induced immunosuppression
|
|
AU2003213640A1
(en)
*
|
2002-02-28 |
2003-09-16 |
Corixa Corporation |
Methods of modulating dendritic cells using adjuvants
|
|
CA2479118A1
(en)
*
|
2002-03-15 |
2003-09-25 |
Wyeth Holdings Corporation |
Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
|
|
JP5014573B2
(ja)
|
2002-05-09 |
2012-08-29 |
オンコサイレオン インコーポレーテッド |
脂質aおよび他の炭水化物リガンド類似体
|
|
US7288640B2
(en)
*
|
2002-07-08 |
2007-10-30 |
Corixa Corporation |
Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
|
|
NZ537655A
(en)
*
|
2002-07-08 |
2006-12-22 |
Corixa Corp |
Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
|
|
US7785608B2
(en)
*
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
|
US7301554B2
(en)
*
|
2002-09-20 |
2007-11-27 |
Ricoh Company, Ltd. |
Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
|
|
US7387271B2
(en)
*
|
2002-12-30 |
2008-06-17 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
|
SI1589934T1
(sl)
*
|
2003-01-06 |
2016-02-29 |
Corixa Corporation Corporation Service Company |
Določene aminoalkil glukozaminid fosfat spojine in njih uporaba
|
|
US7960522B2
(en)
*
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
JP2006517974A
(ja)
*
|
2003-02-13 |
2006-08-03 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物およびトル様受容体8に関する方法および組成物
|
|
EP1599726A4
(en)
*
|
2003-02-27 |
2009-07-22 |
3M Innovative Properties Co |
SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
|
|
WO2004078138A2
(en)
|
2003-03-04 |
2004-09-16 |
3M Innovative Properties Company |
Prophylactic treatment of uv-induced epidermal neoplasia
|
|
AU2004220465A1
(en)
|
2003-03-13 |
2004-09-23 |
3M Innovative Properties Company |
Method of tattoo removal
|
|
KR20050109562A
(ko)
*
|
2003-03-13 |
2005-11-21 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
피부의 질을 개선시키는 방법
|
|
US20040192585A1
(en)
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
|
AU2004229478B2
(en)
*
|
2003-04-10 |
2009-12-24 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
|
JP2007501252A
(ja)
*
|
2003-08-05 |
2007-01-25 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調整剤を含有する製剤
|
|
WO2005018556A2
(en)
|
2003-08-12 |
2005-03-03 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazo-containing compounds
|
|
US20050048072A1
(en)
*
|
2003-08-25 |
2005-03-03 |
3M Innovative Properties Company |
Immunostimulatory combinations and treatments
|
|
RU2006105101A
(ru)
|
2003-08-27 |
2007-10-10 |
3М Инновейтив Пропертиз Компани (US) |
Арилокси и арилалкиленокси замещенные имидазохинолины
|
|
WO2005023190A2
(en)
*
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for cd5+ b cell lymphoma
|
|
US8871782B2
(en)
|
2003-10-03 |
2014-10-28 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
|
AU2004285575A1
(en)
*
|
2003-10-31 |
2005-05-12 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
|
CA2545774A1
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Oxime substituted imidazo ring compounds
|
|
US8598192B2
(en)
|
2003-11-14 |
2013-12-03 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazoquinolines
|
|
AR046781A1
(es)
|
2003-11-25 |
2005-12-21 |
3M Innovative Properties Co |
Derivados de imidazoquinolinas. composiciones farmaceuticas.
|
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
|
JP2007513165A
(ja)
*
|
2003-12-02 |
2007-05-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物を含む併用薬および治療方法
|
|
SG149013A1
(en)
|
2003-12-17 |
2009-01-29 |
Wyeth Corp |
Immunogenic peptide carrier conjugates and methods of producing same
|
|
SI2336147T1
(sl)
|
2003-12-17 |
2014-08-29 |
Janssen Alzheimer Immunotherapy |
Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
|
|
WO2005066170A1
(en)
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
|
WO2005067500A2
(en)
*
|
2003-12-30 |
2005-07-28 |
3M Innovative Properties Company |
Enhancement of immune responses
|
|
CA2551399A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
|
AU2005228150A1
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
|
CA2564855A1
(en)
*
|
2004-04-28 |
2005-10-28 |
3M Innovative Properties Company |
Compositions and methods for mucosal vaccination
|
|
GB0410220D0
(en)
|
2004-05-07 |
2004-06-09 |
Kirkham Lea Ann |
Mutant pneumolysin proteins
|
|
US7771731B2
(en)
|
2004-05-21 |
2010-08-10 |
Wyeth Llc |
Altered fibronectin-binding protein of Staphylococcus aureus
|
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
|
WO2005123080A2
(en)
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
|
WO2006038923A2
(en)
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
|
WO2006065280A2
(en)
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
|
US8026366B2
(en)
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
|
WO2006026470A2
(en)
*
|
2004-08-27 |
2006-03-09 |
3M Innovative Properties Company |
Hiv immunostimulatory compositions
|
|
JP2008515928A
(ja)
*
|
2004-10-08 |
2008-05-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
Dnaワクチンのためのアジュバント
|
|
BRPI0516974A
(pt)
|
2004-10-21 |
2008-09-30 |
Wyeth Corp |
composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis
|
|
JP2008526765A
(ja)
|
2004-12-30 |
2008-07-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
皮膚転移の処置
|
|
AU2005326708C1
(en)
|
2004-12-30 |
2012-08-30 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
|
EP1831226B1
(en)
|
2004-12-30 |
2012-08-08 |
3M Innovative Properties Company |
Chiral tetracyclic compounds inducing interferon biosynthesis
|
|
AU2006210392A1
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune response modifiers
|
|
CA2597587A1
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
|
US7943636B2
(en)
|
2005-04-01 |
2011-05-17 |
3M Innovative Properties Company |
1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
|
WO2006107853A2
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
|
US7709001B2
(en)
|
2005-04-08 |
2010-05-04 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
IL308456A
(en)
|
2005-04-08 |
2024-01-01 |
Wyeth Llc |
A multivalent pneumomuroral protein-polysaccharide conjugate preparation
|
|
CA2605808A1
(en)
*
|
2005-04-25 |
2006-11-02 |
3M Innovative Properties Company |
Immunostimulatory compositions
|
|
US20080213318A1
(en)
*
|
2005-07-05 |
2008-09-04 |
Hawaii Biotech, Inc. |
Malaria MSP-1 C-terminal enhanced subunit vaccine
|
|
JP5792920B2
(ja)
|
2005-12-22 |
2015-10-14 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ワクチン
|
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
EP1988896A4
(en)
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
|
NZ570805A
(en)
|
2006-03-30 |
2011-10-28 |
Glaxosmithkline Biolog Sa |
Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
ES2539042T3
(es)
|
2006-06-02 |
2015-06-25 |
Glaxosmithkline Biologicals S.A. |
Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia
|
|
US7906506B2
(en)
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
|
JP5222289B2
(ja)
|
2006-07-18 |
2013-06-26 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
マラリア用ワクチン
|
|
US8323664B2
(en)
|
2006-07-25 |
2012-12-04 |
The Secretary Of State For Defence |
Live vaccine strains of Francisella
|
|
EP2433648A3
(en)
|
2006-10-12 |
2012-04-04 |
GlaxoSmithKline Biologicals S.A. |
Vaccine comprising an oil in water emulsion adjuvant
|
|
US20090285819A1
(en)
*
|
2006-11-15 |
2009-11-19 |
Functional Genetics, Inc. |
Methods and compositions for treating influenza
|
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
|
CN103550764A
(zh)
|
2007-03-02 |
2014-02-05 |
葛兰素史密丝克莱恩生物有限公司 |
疫苗组合物及其在刺激免疫反应中的用途
|
|
WO2008124647A2
(en)
|
2007-04-04 |
2008-10-16 |
Infectious Disease Research Institute |
Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
|
|
US9452209B2
(en)
|
2007-04-20 |
2016-09-27 |
Glaxosmithkline Biologicals Sa |
Influenza vaccine
|
|
EA200901578A1
(ru)
|
2007-06-26 |
2010-08-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
|
|
WO2009016639A2
(en)
|
2007-08-02 |
2009-02-05 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope influenza vaccines
|
|
NZ596545A
(en)
|
2007-09-17 |
2013-05-31 |
Glaxosmithkline Biolog Sa |
Improved detection of mage-a expression
|
|
US20090215710A1
(en)
*
|
2007-09-24 |
2009-08-27 |
Reliance Life Sciences Pvt. Ltd. |
Carbohydrate based toll-like receptor (tlr) antagonists
|
|
ES2626634T3
(es)
|
2007-12-19 |
2017-07-25 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Formas solubles de la glucoproteína F del virus de Hendra y Nipah y usos de la misma
|
|
WO2009082664A2
(en)
*
|
2007-12-21 |
2009-07-02 |
Wyeth |
Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
|
|
US8563002B2
(en)
|
2007-12-24 |
2013-10-22 |
Glaxosmithkline Biologicals, S.A. |
Recombinant RSV antigens
|
|
WO2009126822A2
(en)
|
2008-04-09 |
2009-10-15 |
The University Of North Carolina At Chapel Hill |
Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
|
|
KR20110009157A
(ko)
|
2008-04-16 |
2011-01-27 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신
|
|
WO2009155484A2
(en)
|
2008-06-20 |
2009-12-23 |
Wyeth |
Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
|
|
AU2009313615B2
(en)
|
2008-11-05 |
2012-11-29 |
Regents Of The University Of Minnesota |
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
|
|
JP2012510289A
(ja)
|
2008-12-03 |
2012-05-10 |
プロティア ワクチン テクノロジーズ リミテッド |
グルタミルtRNA合成酵素(GtS)フラグメント
|
|
CA2748038A1
(en)
*
|
2008-12-23 |
2010-07-01 |
Glaxosmithkline Biologicals S.A. |
Method for inducing a trif-bias
|
|
WO2010079081A1
(en)
|
2009-01-07 |
2010-07-15 |
Glaxosmithkline Biologicals S.A. |
Methods for recovering a virus or a viral antigen produced by cell culture
|
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
|
WO2010089339A1
(en)
|
2009-02-06 |
2010-08-12 |
Glaxosmithkline Biologicals S.A. |
Purification of virus or viral antigens by density gradient ultracentrifugation
|
|
NZ700477A
(en)
|
2009-02-17 |
2016-04-29 |
Glaxosmithkline Biolog Sa |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
|
BRPI1009873A2
(pt)
|
2009-03-17 |
2016-03-08 |
Glaxosmithkline Biolog Sa |
detecção aperfeiçoada de expressão gênica
|
|
MX2011010616A
(es)
*
|
2009-04-09 |
2012-03-14 |
Univ North Carolina |
Metodos para tratar edema relacionado a isquemia-reperfusion.
|
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
|
AU2010264538B2
(en)
|
2009-06-22 |
2013-10-03 |
Wyeth Llc |
Immunogenic compositions of Staphylococcus aureus antigens
|
|
WO2011041003A2
(en)
|
2009-06-22 |
2011-04-07 |
Wyeth Llc |
Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
|
|
PL2445526T3
(pl)
|
2009-06-24 |
2017-08-31 |
Glaxosmithkline Biologicals S.A. |
Rekombinowane antygeny rsv
|
|
SG176807A1
(en)
|
2009-06-24 |
2012-01-30 |
Id Biomedical Corp Quebec |
Vaccine
|
|
US9907746B2
(en)
|
2009-07-06 |
2018-03-06 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
|
MX2012000372A
(es)
|
2009-07-06 |
2012-02-28 |
Variation Biotechnologies Inc |
Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
|
|
EP4183412B1
(en)
|
2009-07-15 |
2024-08-14 |
GlaxoSmithKline Biologicals SA |
Rsv f protein compositions and methods for making same
|
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
|
GB0917457D0
(en)
|
2009-10-06 |
2009-11-18 |
Glaxosmithkline Biolog Sa |
Method
|
|
JP5774010B2
(ja)
|
2009-09-25 |
2015-09-02 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
インフルエンザウイルスのための免疫拡散アッセイ
|
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
|
EP2566958B1
(en)
|
2010-05-03 |
2015-12-30 |
GlaxoSmithKline Biologicals S.A. |
Method for inactivating influenza virus
|
|
GB201009273D0
(en)
|
2010-06-03 |
2010-07-21 |
Glaxosmithkline Biolog Sa |
Novel vaccine
|
|
EP3626263A1
(en)
|
2010-06-04 |
2020-03-25 |
Wyeth LLC |
Vaccine formulations
|
|
CA2840079C
(en)
|
2010-07-06 |
2018-07-03 |
Variation Biotechnologies Inc. |
Compositions and methods for treating influenza
|
|
CA2808975C
(en)
|
2010-08-23 |
2018-10-30 |
Wyeth Llc |
Stable formulations of neisseria meningitidis rlp2086 antigens
|
|
KR101584871B1
(ko)
|
2010-09-10 |
2016-01-22 |
와이어쓰 엘엘씨 |
네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
|
|
GB201101331D0
(en)
|
2011-01-26 |
2011-03-09 |
Glaxosmithkline Biolog Sa |
Compositions and uses
|
|
SG190937A1
(en)
|
2010-12-14 |
2013-07-31 |
Glaxosmithkline Biolog Sa |
Mycobacterium antigenic composition
|
|
HUE033072T2
(hu)
|
2010-12-22 |
2017-11-28 |
Wyeth Llc |
Staphylococcus aureus antigének immunogén készítményei
|
|
US10736844B2
(en)
|
2011-01-13 |
2020-08-11 |
Variation Biotechnologies Inc. |
Compositions and methods for treating viral infections
|
|
WO2012114323A1
(en)
|
2011-02-22 |
2012-08-30 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
|
JP2014518841A
(ja)
|
2011-02-24 |
2014-08-07 |
オンコシレオン インク. |
アジュバントを備えたmuc1ベースのグリコリポペプチドワクチン
|
|
RS56748B1
(sr)
|
2011-05-13 |
2018-03-30 |
Glaxosmithkline Biologicals Sa |
Pre-fuzioni rsv f antigeni
|
|
KR20140033127A
(ko)
|
2011-05-17 |
2014-03-17 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
스트렙토코쿠스 뉴모니애에 대한 백신
|
|
EP3153180A1
(en)
|
2011-06-03 |
2017-04-12 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
|
BR112013031028A2
(pt)
|
2011-06-03 |
2016-11-29 |
3M Innovative Properties Co |
conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
|
|
ITMI20111182A1
(it)
|
2011-06-28 |
2012-12-29 |
Canio Buonavoglia |
Vaccino per coronavirus canino
|
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
GB201116248D0
(en)
|
2011-09-20 |
2011-11-02 |
Glaxosmithkline Biolog Sa |
Liposome production using isopropanol
|
|
GB201119999D0
(en)
|
2011-11-20 |
2012-01-04 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
GB201120000D0
(en)
|
2011-11-20 |
2012-01-04 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
CA2894442C
(en)
|
2012-01-12 |
2020-01-21 |
Variation Biotechnologies Inc. |
Compositions and methods for treating viral infections
|
|
EP4008354A1
(en)
|
2012-01-27 |
2022-06-08 |
Variation Biotechnologies Inc. |
Methods and compositions for therapeutic agents
|
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
|
CA2865745C
(en)
|
2012-03-09 |
2018-01-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
|
CN104203270A
(zh)
|
2012-03-18 |
2014-12-10 |
葛兰素史密丝克莱恩生物有限公司 |
针对人乳头状瘤病毒的接种方法
|
|
ES2702278T3
(es)
|
2012-04-01 |
2019-02-28 |
Technion Res & Dev Foundation |
Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
|
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
CA2879443A1
(en)
|
2012-07-19 |
2014-01-23 |
Zoetis Llc |
Bovine influenza virus compositions
|
|
WO2014018724A1
(en)
|
2012-07-27 |
2014-01-30 |
Zoetis Llc |
Tick toxin compositions
|
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
|
SG11201500573RA
(en)
|
2012-08-06 |
2015-02-27 |
Glaxosmithkline Biolog Sa |
Method for eliciting in infants an immune response against rsv and b. pertussis
|
|
PT2885007T
(pt)
|
2012-08-16 |
2018-12-10 |
Pfizer |
Processos e composições de glicoconjugação
|
|
KR20140075196A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
RU2672053C2
(ru)
|
2012-12-20 |
2018-11-09 |
Пфайзер Инк. |
Способ гликоконъюгации
|
|
CA2840937A1
(en)
|
2013-02-05 |
2014-08-05 |
Nitto Denko Corporation |
Vaccine composition for transdermal administration
|
|
CN103961701B
(zh)
|
2013-02-05 |
2018-09-14 |
日东电工株式会社 |
疫苗组合物
|
|
CN103961702B
(zh)
|
2013-02-05 |
2019-04-09 |
日东电工株式会社 |
粘膜给予用wt1肽癌症疫苗组合物
|
|
CA2840954A1
(en)
|
2013-02-05 |
2014-08-05 |
Nitto Denko Corporation |
Vaccine composition for transdermal or mucosal administration
|
|
CN103961697A
(zh)
|
2013-02-05 |
2014-08-06 |
日东电工株式会社 |
粘膜给予用疫苗组合物
|
|
CA2840941A1
(en)
|
2013-02-05 |
2014-08-05 |
Nitto Denko Corporation |
Wt1 peptide cancer vaccine composition for transdermal administration
|
|
CA2841014A1
(en)
|
2013-02-05 |
2014-08-05 |
Nitto Denko Corporation |
Tape preparation of wt1 peptide cancer vaccine for transdermal administration
|
|
CA2840997A1
(en)
|
2013-02-05 |
2014-08-05 |
Nitto Denko Corporation |
Vaccine composition for transdermal administration
|
|
CN103961700A
(zh)
|
2013-02-05 |
2014-08-06 |
日东电工株式会社 |
粘膜给予用疫苗组合物
|
|
CN103961307B
(zh)
|
2013-02-05 |
2019-11-29 |
日东电工株式会社 |
经皮给予用wt1肽癌症疫苗组合物
|
|
CA2903716C
(en)
|
2013-03-08 |
2019-04-09 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
|
EP4421177A3
(en)
|
2013-03-13 |
2024-12-18 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Prefusion rsv f proteins and their use
|
|
CA2907098A1
(en)
|
2013-03-15 |
2014-09-25 |
Zoetis Services Llc |
Cross-protection of bovines against b. trehalosi infection by a multi-valent vaccine
|
|
WO2014141127A1
(en)
|
2013-03-15 |
2014-09-18 |
Glaxosmithkline Biologicals S.A. |
Composition containing buffered aminoalkyl glucosaminide phosphate derivatives and its use for enhancing an immune response
|
|
US10058603B2
(en)
|
2013-03-15 |
2018-08-28 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
|
EP2978447B1
(en)
|
2013-03-28 |
2019-05-08 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
|
US10260038B2
(en)
|
2013-05-10 |
2019-04-16 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
|
SG11201600709TA
(en)
|
2013-08-05 |
2016-02-26 |
Glaxosmithkline Biolog Sa |
Combination immunogenic compositions
|
|
BE1022132B1
(fr)
|
2013-08-30 |
2016-02-19 |
Glaxosmithkline Biologicals S.A. |
Nouvelle methode.
|
|
RU2662968C2
(ru)
|
2013-09-08 |
2018-07-31 |
Пфайзер Инк. |
Иммуногенная композиция против neisseria meningitidis (варианты)
|
|
JP2015059577A
(ja)
|
2013-09-17 |
2015-03-30 |
Ntn株式会社 |
チェーン伝動装置
|
|
CN104436157A
(zh)
|
2013-09-23 |
2015-03-25 |
恩金生物有限公司 |
流感疫苗和治疗
|
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
|
WO2015095868A1
(en)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
|
BR112016015835B1
(pt)
|
2014-01-21 |
2023-12-26 |
Pfizer Inc |
Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
|
|
FI3583947T3
(fi)
|
2014-01-21 |
2023-10-12 |
Pfizer |
Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit
|
|
WO2016130569A1
(en)
|
2015-02-09 |
2016-08-18 |
Mj Biologics, Inc. |
A composition comprising pedv antigens and methods for making and using the composition
|
|
ES2930318T3
(es)
|
2014-02-14 |
2022-12-09 |
Pfizer |
Conjugados glucoproteicos inmunogénicos
|
|
WO2015130584A2
(en)
|
2014-02-25 |
2015-09-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
EP3116539B1
(en)
|
2014-03-11 |
2018-10-10 |
Regents of the University of Minnesota |
Porcine epidemic diarrhea virus vaccines and methods of use thereof
|
|
CN106456546A
(zh)
|
2014-03-12 |
2017-02-22 |
葛兰素史密丝克莱恩生物有限公司 |
用于黏膜递送的脂质体组合物
|
|
AU2015228387A1
(en)
|
2014-03-12 |
2016-10-27 |
Glaxosmithkline Biologicals S.A. |
Immunogenic liposomal formulation
|
|
US10426828B2
(en)
|
2014-04-03 |
2019-10-01 |
Biondvax Pharmaceuticals Ltd. |
Compositions of multimeric-multiepitope influenza polypeptides and their production
|
|
EP3154576A1
(en)
|
2014-06-13 |
2017-04-19 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic combinations
|
|
WO2016012385A1
(en)
|
2014-07-21 |
2016-01-28 |
Sanofi Pasteur |
Vaccine composition comprising ipv and cyclodextrins
|
|
AR102548A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
|
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
|
WO2016109880A1
(en)
|
2015-01-06 |
2016-07-14 |
Immunovaccine Technologies Inc. |
Lipid a mimics, methods of preparation, and uses thereof
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
KR20190049940A
(ko)
|
2015-02-19 |
2019-05-09 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
|
WO2016140702A1
(en)
|
2015-03-03 |
2016-09-09 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces |
Display platform from bacterial spore coat proteins
|
|
JP6570648B2
(ja)
|
2015-03-12 |
2019-09-04 |
ゾエティス・サービシーズ・エルエルシー |
ピオリシン方法及び組成物
|
|
KR102143534B1
(ko)
|
2015-05-04 |
2020-08-12 |
화이자 인코포레이티드 |
B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
|
|
US10682314B2
(en)
|
2015-05-26 |
2020-06-16 |
Ohio State Innovation Foundation |
Nanoparticle based vaccine strategy against swine influenza virus
|
|
BR112018002520A2
(pt)
|
2015-08-06 |
2018-09-18 |
Glaxosmithkline Ip Dev Ltd |
Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
|
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
|
DK3334454T3
(da)
|
2015-08-14 |
2022-11-14 |
Zoetis Services Llc |
Mycoplasma-Bovis-sammensætninger
|
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
|
CN108367062B
(zh)
|
2015-10-13 |
2022-05-06 |
赛诺菲巴斯德有限公司 |
抗金黄色葡萄球菌的免疫原性组合物
|
|
CR20180229A
(es)
|
2015-10-29 |
2018-08-24 |
Novartis Ag |
Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
|
|
JP6411676B2
(ja)
|
2015-12-03 |
2018-10-24 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Stingの調節因子としての環状プリンジヌクレオチド
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
WO2017097783A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Biologicals S.A. |
Novel adjuvant formulations
|
|
CA3010977A1
(en)
|
2016-01-11 |
2017-07-20 |
Zoetis Services Llc |
Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
|
|
WO2017137085A1
(en)
|
2016-02-11 |
2017-08-17 |
Sanofi Pasteur |
Meningitidis vaccines comprising subtilinases
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
SG10201900628RA
(en)
|
2016-04-07 |
2019-02-27 |
Glaxosmithkline Ip Dev Ltd |
Heterocyclic amides useful as protein modulators
|
|
WO2017175156A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
WO2017191545A1
(en)
|
2016-05-05 |
2017-11-09 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
US11033615B2
(en)
|
2016-05-31 |
2021-06-15 |
The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland |
Zika virus vaccine and methods of production
|
|
EP3474890B1
(en)
|
2016-06-22 |
2026-05-06 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
|
EP3269385A1
(en)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
|
CN109789135A
(zh)
|
2016-07-20 |
2019-05-21 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为perk抑制剂的异喹啉衍生物
|
|
MX2019002178A
(es)
|
2016-08-23 |
2019-09-18 |
Glaxosmithkline Biologicals Sa |
Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
|
|
WO2018053294A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
CN110225983A
(zh)
|
2016-12-01 |
2019-09-10 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的方法
|
|
CA3045952A1
(en)
|
2016-12-07 |
2018-06-14 |
Glaxosmithkline Biologicals Sa |
Novel process
|
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
|
WO2018109220A2
(en)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
|
GB201621686D0
(en)
|
2016-12-20 |
2017-02-01 |
Glaxosmithkline Biologicals Sa |
Novel methods for inducing an immune response
|
|
SG11201906519RA
(en)
|
2017-01-31 |
2019-08-27 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
|
CN110225757A
(zh)
|
2017-01-31 |
2019-09-10 |
默沙东公司 |
由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
|
|
WO2018144439A1
(en)
|
2017-01-31 |
2018-08-09 |
Merck Sharp & Dohme Corp. |
Methods for making polysaccharide-protein conjugates
|
|
CN110392690B
(zh)
|
2017-02-24 |
2024-01-30 |
默沙东有限责任公司 |
肺炎球菌缀合物疫苗制剂
|
|
GB201703529D0
(en)
|
2017-03-06 |
2017-04-19 |
Cambridge Entpr Ltd |
Vaccine composition
|
|
WO2018183666A1
(en)
|
2017-03-31 |
2018-10-04 |
Boston Medical Center Corporation |
Methods and compositions using highly converved pneumococcal surface proteins
|
|
EP3612562A2
(en)
|
2017-04-19 |
2020-02-26 |
Institute for Research in Biomedicine |
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
|
|
US20210187098A1
(en)
|
2017-04-28 |
2021-06-24 |
Glaxosmithkline Biologicals Sa |
Vaccination
|
|
WO2018204302A1
(en)
|
2017-05-01 |
2018-11-08 |
Vanderbilt University |
Phosphorylated hexaacyl disaccharides (phads) for treating or preventing infections
|
|
GB201707700D0
(en)
|
2017-05-12 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Dried composition
|
|
GB2600652B
(en)
|
2017-05-30 |
2022-11-02 |
Glaxosmithkline Biologicals Sa |
Novel compositions
|
|
BR112019025104A2
(pt)
|
2017-05-30 |
2020-06-23 |
Glaxosmithkline Biologicals S.A. |
Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição
|
|
SG11201912601RA
(en)
|
2017-06-23 |
2020-01-30 |
Nosocomial Vaccine Corp |
Immunogenic compositions
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
HUE068482T2
(hu)
|
2017-09-07 |
2025-01-28 |
Merck Sharp & Dohme Llc |
Pneumococcus-poliszacharidok és azok felhasználása immunogén poliszacharid-hordozóprotein konjugátumokban
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
KR20200051778A
(ko)
|
2017-09-13 |
2020-05-13 |
사노피 파스퇴르 |
인간 시토메갈로바이러스 면역원성 조성물
|
|
US11377440B2
(en)
|
2017-10-05 |
2022-07-05 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING)
|
|
AU2018344902B2
(en)
|
2017-10-05 |
2021-06-03 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING) useful in treating HIV
|
|
JP7197880B2
(ja)
*
|
2017-10-19 |
2022-12-28 |
学校法人 名城大学 |
エステル化剤及びその利用
|
|
EP3720483B1
(en)
|
2017-12-06 |
2025-11-19 |
Merck Sharp & Dohme LLC |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
BR112020016314A2
(pt)
|
2018-02-12 |
2020-12-15 |
Inimmune Corporation |
Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
|
|
EP3755342A4
(en)
|
2018-02-21 |
2021-11-24 |
The University Of Montana |
DIARYL TREHALOSE CONNECTIONS AND THEIR USES
|
|
MX387358B
(es)
|
2018-02-28 |
2025-03-18 |
Pfizer |
Variantes de il-15 y usos de las mismas
|
|
WO2019169313A1
(en)
|
2018-03-02 |
2019-09-06 |
The University Of Montana |
Immunogenic trehalose compounds and uses thereof
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
US11525010B2
(en)
|
2018-05-23 |
2022-12-13 |
Pfizer Inc. |
Antibodies specific for GUCY2c and uses thereof
|
|
AU2019274654B2
(en)
|
2018-05-23 |
2023-07-20 |
Pfizer Inc. |
Antibodies specific for CD3 and uses thereof
|
|
EP3574915A1
(en)
|
2018-05-29 |
2019-12-04 |
Neovacs |
Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
|
|
MX2020013553A
(es)
|
2018-06-12 |
2021-02-26 |
Glaxosmithkline Biologicals Sa |
Polinucleotidos y polipeptidos de adenovirus.
|
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
|
CN112566654A
(zh)
|
2018-07-31 |
2021-03-26 |
葛兰素史密丝克莱恩生物有限公司 |
抗原纯化方法
|
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
|
WO2020030570A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
|
|
WO2020031087A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
US12239699B2
(en)
|
2018-09-11 |
2025-03-04 |
Shanghai Public Health Clinical Center |
Immunogen for broad-spectrum influenza vaccine and application thereof
|
|
EP3886901A1
(en)
*
|
2018-11-29 |
2021-10-06 |
GlaxoSmithKline Biologicals S.A. |
Methods for manufacturing an adjuvant
|
|
EP3897705A2
(en)
|
2018-12-19 |
2021-10-27 |
Merck Sharp & Dohme Corp. |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
|
EP3897846A1
(en)
|
2018-12-21 |
2021-10-27 |
GlaxoSmithKline Biologicals SA |
Methods of inducing an immune response
|
|
EP3972636A4
(en)
|
2019-05-23 |
2023-08-02 |
The University Of Montana |
VACCINE ADJUVANTS BASED ON TLR RECEPTOR LIGANDS
|
|
CA3143211A1
(en)
|
2019-06-26 |
2020-12-30 |
Glaxosmithkline Intellectual Property Development Limited |
Il1rap binding proteins
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
EP3999093A4
(en)
|
2019-07-19 |
2023-11-22 |
Merck Sharp & Dohme LLC |
ANTIGENIC E GLYCOPROTEIN POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
MX2022000879A
(es)
|
2019-07-21 |
2022-05-02 |
Glaxosmithkline Biologicals Sa |
Vacuna viral terapeutica.
|
|
JP2022542316A
(ja)
|
2019-07-31 |
2022-09-30 |
サノフィ パスツール インコーポレイテッド |
多価肺炎球菌多糖体-タンパク質コンジュゲート組成物およびその使用方法
|
|
WO2021018941A1
(en)
|
2019-07-31 |
2021-02-04 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
|
WO2021038508A1
(en)
|
2019-08-30 |
2021-03-04 |
Glaxosmithkline Biologicals Sa |
Jet mixing lipid nanoparticle manufacturing process
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
CN114466659A
(zh)
|
2019-09-09 |
2022-05-10 |
葛兰素史克生物有限公司 |
免疫治疗组合物
|
|
AU2020355614B2
(en)
|
2019-09-27 |
2024-12-05 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
|
CA3155669A1
(en)
|
2019-09-27 |
2021-04-01 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
|
BR112022008761A2
(pt)
|
2019-11-22 |
2022-07-26 |
Glaxosmithkline Biologicals Sa |
Dosagem e administração de uma vacina de glicoconjugado de sacarídeo
|
|
JP7369297B2
(ja)
|
2019-12-17 |
2023-10-25 |
ファイザー・インク |
Cd47、pd-l1に特異的な抗体、およびその使用
|
|
WO2021119753A1
(en)
|
2019-12-18 |
2021-06-24 |
Ctxt Pty Limited |
Compounds
|
|
EP4103225A2
(en)
|
2020-02-13 |
2022-12-21 |
The Board Of Trustees Of The University Of Illinois |
Vaccine and methods for detecting and preventing filariasis
|
|
WO2021209636A1
(en)
|
2020-04-16 |
2021-10-21 |
Par'immune Sas |
28 kda gst proteins from schistosoma for the treatment of vasculitis
|
|
WO2021211279A1
(en)
|
2020-04-17 |
2021-10-21 |
Regents Of The University Of Minnesota |
SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
|
|
EP3900739A1
(en)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
|
|
BR112022020660A2
(pt)
|
2020-05-05 |
2022-11-29 |
Glaxosmithkline Biologicals Sa |
Dispositivo de mistura microfluídica e métodos de uso
|
|
WO2021245025A1
(en)
|
2020-06-01 |
2021-12-09 |
Loop Diagnostics, S.L. |
Method and kit for the early detection of sepsis
|
|
WO2021245611A1
(en)
|
2020-06-05 |
2021-12-09 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
|
IL299253A
(en)
|
2020-06-22 |
2023-02-01 |
Sumitomo Pharma Co Ltd |
Helps with TLR4 agonist activity
|
|
MX2023000662A
(es)
|
2020-07-17 |
2023-02-27 |
Pfizer |
Anticuerpos terapeuticos y sus usos.
|
|
EP4203995A1
(en)
|
2020-08-26 |
2023-07-05 |
Pfizer Inc. |
Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
|
|
JP2023542141A
(ja)
|
2020-09-15 |
2023-10-05 |
ザ ユニバーシティー オブ モンタナ |
繊維状バクテリオファージを標的化する組成物および方法
|
|
US20230364232A1
(en)
|
2020-09-17 |
2023-11-16 |
Neovacs |
IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS
|
|
TW202233200A
(zh)
|
2020-11-11 |
2022-09-01 |
日商第一三共股份有限公司 |
新穎胺基烷基葡萄胺糖苷4-磷酸衍生物
|
|
JP2023553854A
(ja)
|
2020-12-02 |
2023-12-26 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ドナー鎖補完性fimh
|
|
EP4032547A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Hsv1 fce derived fragements for the treatment of hsv
|
|
WO2022169835A1
(en)
|
2021-02-03 |
2022-08-11 |
The Board Of Trustees Of The University Of Illinois |
Vaccine and methods for preventing filariasis and dirofilariasis
|
|
MX2023009456A
(es)
|
2021-02-11 |
2023-08-28 |
Glaxosmithkline Biologicals Sa |
Preparacion de la vacuna contra el vph.
|
|
CA3212345A1
(en)
|
2021-03-02 |
2022-09-09 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
|
EP4314060A1
(en)
|
2021-03-31 |
2024-02-07 |
GlaxoSmithKline Intellectual Property Development Limited |
Antigen binding proteins and combinations thereof
|
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
US20250082745A1
(en)
|
2021-12-13 |
2025-03-13 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
|
CN114318353B
(zh)
*
|
2021-12-27 |
2023-12-05 |
广东红日星实业有限公司 |
一种除灰剂及其制备方法和应用
|
|
KR20250054810A
(ko)
|
2022-09-29 |
2025-04-23 |
화이자 인코포레이티드 |
Rsv f 단백질 삼량체를 포함하는 면역원성 조성물
|
|
TW202539728A
(zh)
|
2023-11-16 |
2025-10-16 |
美商默沙東有限責任公司 |
肽共軛物疫苗組合物及治療阿茲海默氏症之方法
|
|
EP4656648A1
(en)
|
2024-05-31 |
2025-12-03 |
Consejo Superior De Investigaciones Científicas |
Immunomodulatory thiourea and urea carbohydrate compounds and uses thereof
|
|
WO2026038177A1
(en)
|
2024-08-16 |
2026-02-19 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
CN122325521A
(zh)
*
|
2026-06-08 |
2026-07-03 |
湖南师范大学 |
一种三效价n-乙酰半乳糖胺阳离子脂质体及其制备方法和应用
|